title: Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
abstract: Masseter muscle hypertrophy has been treated for cosmetic purposes using several modalities, including injection of type A or type B botulinum toxin into the masseter muscle. In this report, we compared the efficacy and safety of abobotulinum toxin A with onabotulinum toxin A treatment for masseteric hypertrophy in 25 Korean patients with a conversion factor of 2.5:1 through a controlled, split-face, and evaluator-blinded study. The mean grade of clinical improvement based on clinical assessment was 2.8 ± 0.9 for abobotulinum toxin A and 2.7 ± 0.8 for onabotulinum toxin A at 8 weeks after the injection. At 12 weeks after the injection, the mean grade of clinical improvement based on clinical assessment was 2.9 ± 0.9 for abobotulinum toxin A and 2.7 ± 0.8 for onabotulinum toxin A. More pronounced improvement was observed with abobotulinum toxin A than onabotulinum toxin A in three (12%) patients at 8 weeks and five (20%) patients at 12 weeks. We believe that our data can be used as an essential reference for determining the dose of type A botulinum toxin in the treatment of masseteric hypertrophy.
authors: Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
authors: Soo Hyun
authors: SH
authors: Lee
authors: Seong Ho
authors: SH
authors: Wee
authors: Hyung-Joo
authors: HJ
authors: Kim
authors: Un-Cheol
authors: UC
authors: Yeo
authors: Nam Ho
authors: NH
authors: Lee
authors: Se Won
authors: SW
authors: Lee
authors: Sung Bin
authors: SB
authors: Cho
mesh_terms: D000328:Adult; D044466:Asian People; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006984:Hypertrophy / Q000188:drug therapy; D007273:Injections, Intramuscular; D007723:Korea; D008297:Male; D008406:Masseter Muscle / Q000187:drug effects* / Q000473:pathology; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA